Search
Natamycin
go.drugbank.com/drugs/DB00826ApprovedInvestigationalAmphoteric macrolide antifungal antibiotic from Streptomyces natalensis or S. chattanoogensis. It is used for a variety of fungal infections, mainly topically. [PubChem]
NGX267
go.drugbank.com/drugs/DB05152InvestigationalIt is developed for the treatment of Alzheimer’s disease and has shown the potential to both reduce symptoms and slow disease progression.
AstraZeneca COVID-19 Vaccine
go.drugbank.com/drugs/DB15656ApprovedInvestigational[L12669,L32649] The ChAdOx1 viral vector was developed at the University of Oxford and has been investigated as a potential vector for vaccines against another human coronavirus, Middle Eastern respiratory … clots in association with thrombocytopenia - a causal link with the vaccine has not been proven, but is possible and requires further analysis.
Carlumab
go.drugbank.com/drugs/DB12718ApprovedWithdrawnCarlumab has been used in trials studying the treatment of Cancer and Prostate Cancer.
Rapacuronium
go.drugbank.com/drugs/DB04834ApprovedWithdrawnRapacuronium was withdrawn in 2001 in many countries due to risk of fatal bronchospasm.
Repotrectinib
go.drugbank.com/drugs/DB16826ApprovedInvestigational[A262061] Although resistance to multiple TKI has been reported, including [crizotinib], [lorlatinib], [taletrectinib], and [entrectinib], there has been no reported case of repotrectinib resistance. … This approval is based on favorable results from the TRIDENT-1 study, where the objective response rate was 79% in TKI-naive patients and 38% in TKI-pretreated patients respectively.[L48741]
Interferon alfacon-1
go.drugbank.com/drugs/DB00069ApprovedWithdrawnThis protein has a molecular weight of 19,434 daltons. … Four additional amino acid changes were made to facilitate the molecular construction, and a corresponding synthetic DNA sequence was constructed using chemical synthesis methodology.
Prenylamine
go.drugbank.com/drugs/DB04825ApprovedWithdrawnPrenylamine was withdrawn from the Canadian, US, and UK markets in 1988 due to concerns regarding cardiac arrhythmias.
Lumiliximab
go.drugbank.com/drugs/DB06162InvestigationalLumiliximab was developed by IDEC Pharmaceuticals, which was acquired by Biogen. Clinical trials for CLL were terminated in 2010, and for allergic asthma in 2007. … Lumiliximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug.
2,2'-Dibenzothiazyl disulfide
go.drugbank.com/drugs/DB14201Approved2,2'-Dibenzothiazyl disulfide is an accelerator used in the processing process for natural and synthetic rubber and plastic regeneration. It is also a known allergen and dermatological sensitizer. Sensitivity to 2,2'-Dibenzothiazyl disul...
Synonyms: BTS-SBT, Bis(2-benzothiazyl) disulfide